| Literature DB >> 27052070 |
Manoj Kumar Sahu1, Bharat Siddharth, Arin Choudhury, Sreenivas Vishnubhatla, Sarvesh Pal Singh, Ramesh Menon, Poonam Malhotra Kapoor, Sachin Talwar, Shiv Choudhary, Balram Airan.
Abstract
BACKGROUND: Nosocomial infections (NIs) in the postoperative period not only increase morbidity and mortality, but also impose a significant economic burden on the health care infrastructure. This retrospective study was undertaken to (a) evaluate the incidence, characteristics, risk factors and outcomes of NIs and (b) identify common microorganisms responsible for infection and their antibiotic resistance profile in our Cardiac Surgical Intensive Care Unit (CSICU). PATIENTS AND METHODS: After ethics committee approval, the CSICU records of all patients who underwent cardiovascular surgery between January 2013 and December 2014 were reviewed retrospectively. The incidence of NI, distribution of NI sites, types of microorganisms and their antibiotic resistance, length of CSICU stay, and patient-outcome were determined.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27052070 PMCID: PMC4900368 DOI: 10.4103/0971-9784.179625
Source DB: PubMed Journal: Ann Card Anaesth ISSN: 0971-9784
Distribution of study characteristics between patients with and without nosocomial infections
| Characteristic | Infected ( | Non-infected ( | |
|---|---|---|---|
| Age (years) | |||
| Mean±SD | 20.0±25.43 | 25.0±22.68 | <0.01 |
| <1 year | 41.8 | 12.8 | <0.001 |
| 1-5 | 11.9 | 15.3 | |
| 5-15 | 4.4 | 16.8 | |
| 15-40 | 16.0 | 25.6 | |
| 40-60 | 12.9 | 17.5 | |
| >60 | 12.9 | 11.9 | |
| CPB time# (min) | 109.2±38.76 | 97.5±49.25 | <0.001 |
| Aortic clamp time* (min) | 60.0±22.82 | 60.7±32.02 | 0.77 |
| Ventilation (h) | 14.8±13.38 | 12.1±14.08 | <0.001 |
| ICU stay (days) | 13.6±18.52 | 3.3±3.05 | <0.001 |
| Patient category | |||
| Nonvalvular | 18.8 | 17.1 | <0.001 |
| Valvular | 17.2 | 28.2 | |
| Cyanotic | 38.2 | 25.2 | |
| Acyanotic | 21.0 | 26.2 | |
| Miscellaneous | 4.7 | 3.3 | |
| Cyanotic | 38.2 | 25.2 | |
| Other | 61.8 | 74.8 | <0.001 |
*Excluding surgeries without ACC, #Based on surgeries with CPB. Nonvalvular: CABG, Aortic aneurysms and dissections, Valvular: All valve repairs and replacements, Cyanotics: All right to left shunts and univentricular hearts, Acyanotics: All left to right shunts, Miscellaneous: All closed heart surgeries like PDA ligation, Coarctation repair and pericardiectomy, etc. ACC: Aortic cross clamp, CPB: Cardiopulmonary bypass, ICU: Intensive Care Unit, PDA: Patent ductus arteriosus, CABG: Coronary artery bypass grafting
Figure 1Depicts the source of infection in number of cases with percentage
Figure 2Depicts the causative microorganisms responsible for nosocomial infection and their frequency
Figure 3Causative microorganisms isolated from different sources
Antibiotic resistance profile n (%) of microorganisms
| Drug | Organism | |||||
|---|---|---|---|---|---|---|
| Colistin | 23/126 (18.3) (11.4-25.1) | 3/71 (4) (0.5-9) | 1/48 (2) (2-6) | 9/32 (28) (11-44) | 4/33 (12) (0.3-23) | 0/9 (0) |
| Tigecycline | 68/106 (64.2) (54-73) | 3/29 (10) (1-22) | 1/14 (7) (8-22) | 3/12 (25) (3-53) | 3/15 (20) (2-42) | 3/8 (37) (0-80) |
| Amikacin | 98/121 (81.0) (73-88) | 54/63 (86) (76-94) | 38/45 (84) (73-95) | 26/43 (60) (45-75) | 22/33 (66) (49-83) | 13/37 (35) (18-51) |
| Netilmicin | 126/134 (94.0) (89-98) | 69/73 (95) (89-99) | 32/38 (84) (72-96) | 40/47 (85) (74-95) | 30/34 (88) (76-99) | 39/46 (85) (73-95) |
| Ciprofloxacin | 125/128 (97.7) (94-100) | 70/76 (92) (85-98) | 48/50 (96) (90-100) | 48/52 (92) (84-99) | 31/38 (82) (68-94) | 42/46 (91) (82-99) |
| Levofoxacin | - | - | 19/22 (86) (70-100) | 30/32 (94) (84-102) | 10/18 (55) (30-80) | 3/4 (75) (0-100) |
| Ceftazidime | 136/136 (100.0) (-) | 78/78 (100) (-) | 53/53 (100) (-) | 53/53 (100) (-) | 38/38 (100) (-) | 17/17 (100) (-) |
| Cefotaxime | 135/135 (100.0) (-) | 77/77 (100) (-) | 33/33 (100) (-) | 51/51 (100) (1) | 37/37 (100) (-) | 17/17 (100) (-) |
| Cefoperazone-sulbactam | 70/98 (71.4) (62-80) | 53/62 (85) (76-94) | 22/51 (43) (29-57) | 33/43 (77) (63-89) | 22/30 (73) (56-90) | 8/14 (57) (27-86) |
| Piperacilin-tazobactum | 73/116 (62.9) (54-71) | 56/73 (77) (66-86) | 15/41 (36) (21-51) | 25/48 (52) (37-66) | 24/37 (65) (48-81) | 9/11 (82) (54-108) |
| Imipenum | 118/137 (86.1) (80-91) | 68/75 (90) (83-97) | 53/55 (96) (91-100) | 46/54 (85) (75-94) | 37/38 (97) (92-102) | 20/20 (100) (-) |
| Meropenem | 104/127 (81.9) (75-88) | 62/7 (86) (77-94) | 43/51 (84) (73-94) | 37/51 (72) (59-85) | 29/35 (83) (69-95) | 20/22 (90) (77-103) |
| Nitrofurantoin | - | - | 31/32 (97) (90-100) | 8/10 (80) (49-110) | 4/4 (100) (-) | - |
| Amoxicillin-clavulinic acid | 119/121 (98.4) (96-100) | 15/15 (100) (-) | 24/25 (96) (87-104) | 47/49 (96) (90-101) | 26/27 (96) (88-103) | 17/39 (43) (27-59) |
| Vancomycin | - | - | - | - | - | 0/12 (0) |
| Teicoplanin | - | - | - | - | - | 1/31 (3) (0-9) |
| Linezolid | - | - | - | - | - | 21/27 (77) (61-94) |
Figure 4Antimicrobial resistance pattern among different microbes